Forest/Nycomed's Daliresp Reaches The Market, But For Fewer Patients Than Expected
Executive Summary
The narrowed indication granted for Forest Laboratories Inc.'s newly approved chronic obstructive pulmonary disease drug Daliresp (roflumilast) means that a quarter of all diagnosed COPD patients, or three million people, will be eligible for treatment, the firm said.